Key takeaways
Hosts: Kevin Dondarski, principal, Deloitte Consulting LLP
Colin Terry, partner, Deloitte UK
Presenters: Nigel Trotman, CFO of Development, Novartis
David Chapman, director, Deloitte MCS Limited
Emily May, manager, Deloitte UK
Karen Taylor, director, Deloitte UK
1.0 Overview CPE credit | Specialized Knowledge
Return on investment in biopharmaceutical R&D has increased for the second consecutive year, to 5.9%, driven by a surge in high-value products entering the late-stage pipeline. However, this progress appears fragile as rising R&D costs continue to pose a challenge to sustainable R&D. We’ll discuss:
- Current state of R&D returns for 20 leading biopharma companies
- Changing pipeline composition and opportunities that exist outside of oncology and infectious diseases
- A bold approach that may be needed to continue uptick in returns and meet growing demand
